Intelligent Bio Solutions Hits 98% Accuracy in Drug Screening Study, Clearing Path for 2026 FDA Submission — Intelligent Bio Solutions Inc.

Event summary

Intelligent Bio Solutions' drug screening system achieved 98% accuracy in detecting opiate codeine across three U.S. clinical sites.
Sensitivity improved from 82% to 94%, while specificity remained at 100% compared to prior study results.
Company plans to submit FDA 510(k) application in September 2026, accelerating its U.S. market entry timeline.
Study results represent the most comprehensive evaluation in the company's FDA 510(k) clinical study program.

The big picture

Intelligent Bio Solutions' study results position it to disrupt the workplace drug testing market with a non-invasive, rapid testing solution. The company's ability to achieve high accuracy and sensitivity could make it a strong competitor in an industry dominated by traditional methods like urine and blood tests. The planned 2026 FDA submission marks a critical milestone in the company's strategy to expand into the U.S. market, where workplace drug testing is a multi-billion dollar industry.

What we're watching

Regulatory Timing: Whether the FDA 510(k) submission in September 2026 will meet the agency's review timeline for market clearance.
Market Adoption: The pace at which employers in safety-critical industries will adopt the system post-FDA approval.
Competitive Positioning: How the system's accuracy and non-invasive nature will differentiate it from existing drug screening methods.